Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer ResearchStrattmont Group
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead candidate, Ensituximab, for chemotherapy refractory colorectal cancer was recently published in the journal, Clinical Cancer Research. The lead author of this study was Dr. Richard Kim from Moffitt Cancer Center in Tampa, Florida. This was a multi-center study that also enrolled patients at several distinguished Cancer Centers including: Johns Hopkins, Duke University, Washington University St Louis, and Rutgers Cancer Institute. Based on encouraging data, a combination clinical study with Ensituximab and IL-15 is in development.